The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Upgrades 2025 full-year CDMO sales and margin outlook
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Subscribe To Our Newsletter & Stay Updated
